XenoPort May Be Beneficiary of Biogen Patent Filings
Further patent applications could provide patent protection until 2032 for Biogen's BG-12, which should benefit XenoPort's '829 drug, an earlier stage derivative of BG-12, with added protection from generic competition.
BIIB is currently up 1.5 percent in pre-market trading, while XNPT is currently unchanged.
Latest Ratings for BIIB
|Aug 2016||Morgan Stanley||Maintains||Overweight|
|Aug 2016||Standpoint Research||Downgrades||Buy||Hold|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.